Skip to main content
Top
Published in: Acta Diabetologica 1/2016

Open Access 01-02-2016 | Original Article

Association of diabetes and diabetes treatment with incidence of breast cancer

Authors: Esther García-Esquinas, Elisabeth Guinó, Gemma Castaño-Vinyals, Beatriz Pérez-Gómez, Javier Llorca, Jone M. Altzibar, Rosana Peiró-Pérez, Vicente Martín, Concepción Moreno-Iribas, Adonina Tardón, Francisco Javier Caballero, Montse Puig-Vives, Marcela Guevara, Tania Fernández Villa, Dolores Salas, Pilar Amiano, Trinidad Dierssen-Sotos, Roberto Pastor-Barriuso, María Sala, Manolis Kogevinas, Nuria Aragonés, Víctor Moreno, Marina Pollán

Published in: Acta Diabetologica | Issue 1/2016

Login to get access

Abstract

Aims

The aim of this study was to evaluate the association of diabetes and diabetes treatment with risk of postmenopausal breast cancer.

Methods

Histologically confirmed incident cases of postmenopausal breast (N = 916) cancer were recruited from 23 Spanish public hospitals. Population-based controls (N = 1094) were randomly selected from primary care center lists within the catchment areas of the participant hospitals. ORs (95 % CI) were estimated using mixed-effects logistic regression models, using the recruitment center as a random effect term. Breast tumors were classified into hormone receptor positive (ER+ or PR+), HER2+ and triple negative (TN).

Results

Diabetes was not associated with the overall risk of breast cancer (OR 1.09; 95 % CI 0.82–1.45), and it was only linked to the risk of developing TN tumors: Among 91 women with TN tumors, 18.7 % were diabetic, while the corresponding figure among controls was 9.9 % (OR 2.25; 95 % CI 1.22–4.15). Regarding treatment, results showed that insulin use was more prevalent among diabetic cases (2.5 %) as compared to diabetic controls (0.7 %); OR 2.98; 95 % CI 1.26–7.01. They also showed that, among diabetics, the risk of developing HR+/HER2− tumors decreased with longer metformin use (ORper year 0.89; 95 % CI 0.81–0.99; based on 24 cases and 43 controls).

Conclusion

This study reinforces the need to correctly classify breast cancers when studying their association with diabetes. Given the low survival rates in women diagnosed with TN breast tumors and the potential impact of diabetes control on breast cancer prevention, more studies are needed to better characterize this association.
Literature
2.
go back to reference Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403CrossRefPubMed Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403CrossRefPubMed
3.
go back to reference Shikata K, Ninomiya T, Kiyohara Y (2013) Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci 104(1):9–14CrossRefPubMed Shikata K, Ninomiya T, Kiyohara Y (2013) Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci 104(1):9–14CrossRefPubMed
4.
go back to reference Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373(9682):2215–2221PubMedCentralCrossRefPubMed Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373(9682):2215–2221PubMedCentralCrossRefPubMed
5.
go back to reference Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG (2012) Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55(6):1607–1618CrossRefPubMed Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG (2012) Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55(6):1607–1618CrossRefPubMed
6.
go back to reference Renehan A, Smith U, Kirkman MS (2010) Linking diabetes and cancer: a consensus on complexity. Lancet 375(9733):2201–2202CrossRefPubMed Renehan A, Smith U, Kirkman MS (2010) Linking diabetes and cancer: a consensus on complexity. Lancet 375(9733):2201–2202CrossRefPubMed
7.
go back to reference Reeves KW, McLaughlin V, Fredman L, Ensrud K, Cauley JA (2012) Components of metabolic syndrome and risk of breast cancer by prognostic features in the study of osteoporotic fractures cohort. Cancer Causes Control 23(8):1241–1251PubMedCentralCrossRefPubMed Reeves KW, McLaughlin V, Fredman L, Ensrud K, Cauley JA (2012) Components of metabolic syndrome and risk of breast cancer by prognostic features in the study of osteoporotic fractures cohort. Cancer Causes Control 23(8):1241–1251PubMedCentralCrossRefPubMed
8.
go back to reference Bowker SL, Richardson K, Marra CA, Johnson JA (2011) Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women. Diabetes Care 34(12):2542–2544PubMedCentralCrossRefPubMed Bowker SL, Richardson K, Marra CA, Johnson JA (2011) Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women. Diabetes Care 34(12):2542–2544PubMedCentralCrossRefPubMed
9.
go back to reference Carstensen B, Witte DR, Friis S (2012) Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 55(4):948–958CrossRefPubMed Carstensen B, Witte DR, Friis S (2012) Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 55(4):948–958CrossRefPubMed
10.
go back to reference Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T et al (2012) Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30(23):2844–2852PubMedCentralCrossRefPubMed Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T et al (2012) Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30(23):2844–2852PubMedCentralCrossRefPubMed
12.
go back to reference Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139PubMedCentralCrossRefPubMed Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139PubMedCentralCrossRefPubMed
13.
go back to reference Maiti B, Kundranda MN, Spiro TP, Daw HA (2010) The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat 121(2):479–483CrossRefPubMed Maiti B, Kundranda MN, Spiro TP, Daw HA (2010) The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat 121(2):479–483CrossRefPubMed
14.
go back to reference Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R et al (1992) Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52(14):3924–3930PubMed Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R et al (1992) Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52(14):3924–3930PubMed
15.
go back to reference Parisot JP, Hu XF, DeLuise M, Zalcberg JR (1999) Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 79(5–6):693–700PubMedCentralCrossRefPubMed Parisot JP, Hu XF, DeLuise M, Zalcberg JR (1999) Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 79(5–6):693–700PubMedCentralCrossRefPubMed
16.
go back to reference Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6(1):1–12CrossRefPubMed Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6(1):1–12CrossRefPubMed
17.
go back to reference Davison Z, de Blacquiere GE, Westley BR, May FE (2011) Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 13(6):504–515PubMedCentralCrossRefPubMed Davison Z, de Blacquiere GE, Westley BR, May FE (2011) Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 13(6):504–515PubMedCentralCrossRefPubMed
18.
19.
go back to reference Haffner SM (1996) Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Horm Res 45(3–5):233–237CrossRefPubMed Haffner SM (1996) Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Horm Res 45(3–5):233–237CrossRefPubMed
21.
go back to reference Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE et al (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8(13):2031–2040CrossRefPubMed Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE et al (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8(13):2031–2040CrossRefPubMed
22.
go back to reference Chen TW, Liang YN, Feng D, Tao LY, Qi K, Zhang HY et al (2013) Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90. J BUON 18(1):51–56PubMed Chen TW, Liang YN, Feng D, Tao LY, Qi K, Zhang HY et al (2013) Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90. J BUON 18(1):51–56PubMed
23.
go back to reference Vazquez-Martin A, Oliveras-Ferraros C, Del BS, Martin-Castillo B, Menendez JA (2011) The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 126(2):355–364CrossRefPubMed Vazquez-Martin A, Oliveras-Ferraros C, Del BS, Martin-Castillo B, Menendez JA (2011) The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 126(2):355–364CrossRefPubMed
24.
go back to reference Ben SI, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27(25):3576–3586CrossRef Ben SI, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27(25):3576–3586CrossRef
25.
go back to reference Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 7(3):e33411PubMedCentralCrossRefPubMed Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 7(3):e33411PubMedCentralCrossRefPubMed
26.
go back to reference Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A (2013) Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE 8(8):e71583PubMedCentralCrossRefPubMed Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A (2013) Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE 8(8):e71583PubMedCentralCrossRefPubMed
27.
go back to reference Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K et al (2014) Metformin does not affect cancer risk: a cohort study in the UK Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 37(9):2522–2532CrossRefPubMed Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K et al (2014) Metformin does not affect cancer risk: a cohort study in the UK Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 37(9):2522–2532CrossRefPubMed
28.
go back to reference Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS (2013) Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 62(7):922–934CrossRefPubMed Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS (2013) Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 62(7):922–934CrossRefPubMed
29.
go back to reference Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM (2012) Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 97(7):E1170–E1175CrossRefPubMed Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM (2012) Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 97(7):E1170–E1175CrossRefPubMed
30.
go back to reference Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH (2012) The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012:413782PubMedCentralCrossRefPubMed Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH (2012) The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012:413782PubMedCentralCrossRefPubMed
31.
go back to reference Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K (2013) Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab 15(4):349–357CrossRefPubMed Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K (2013) Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab 15(4):349–357CrossRefPubMed
32.
go back to reference Janghorbani M, Dehghani M, Salehi-Marzijarani M (2012) Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer 3(4):137–146CrossRefPubMed Janghorbani M, Dehghani M, Salehi-Marzijarani M (2012) Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer 3(4):137–146CrossRefPubMed
34.
go back to reference Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M (2007) Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 39(1):65–67CrossRefPubMed Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M (2007) Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 39(1):65–67CrossRefPubMed
35.
go back to reference Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH et al (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55(1):51–62PubMedCentralCrossRefPubMed Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH et al (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55(1):51–62PubMedCentralCrossRefPubMed
36.
go back to reference Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den Eeden SK, Weiss NS et al (2013) Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care 36:3953–3960PubMedCentralCrossRefPubMed Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den Eeden SK, Weiss NS et al (2013) Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care 36:3953–3960PubMedCentralCrossRefPubMed
37.
go back to reference Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K et al (2012) Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 107(9):1608–1617PubMedCentralCrossRefPubMed Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K et al (2012) Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 107(9):1608–1617PubMedCentralCrossRefPubMed
Metadata
Title
Association of diabetes and diabetes treatment with incidence of breast cancer
Authors
Esther García-Esquinas
Elisabeth Guinó
Gemma Castaño-Vinyals
Beatriz Pérez-Gómez
Javier Llorca
Jone M. Altzibar
Rosana Peiró-Pérez
Vicente Martín
Concepción Moreno-Iribas
Adonina Tardón
Francisco Javier Caballero
Montse Puig-Vives
Marcela Guevara
Tania Fernández Villa
Dolores Salas
Pilar Amiano
Trinidad Dierssen-Sotos
Roberto Pastor-Barriuso
María Sala
Manolis Kogevinas
Nuria Aragonés
Víctor Moreno
Marina Pollán
Publication date
01-02-2016
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 1/2016
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-015-0756-6

Other articles of this Issue 1/2016

Acta Diabetologica 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.